Core Viewpoint - Kanglong Chemical's stock rose by 5.04% to 33.58 CNY per share, with a trading volume of 837 million CNY and a market capitalization of 59.712 billion CNY as of October 29 [1] Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located at No. 6 Taihe Road, Beijing Economic and Technological Development Zone [1] - The main business segments include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and large molecule and cell & gene therapy services (3.28%) [1] Fund Holdings - Ping An Fund has a significant holding in Kanglong Chemical, with the Ping An CSI Medical Innovation ETF (516820) holding 1.3004 million shares, representing 3.04% of the fund's net value, ranking as the tenth largest holding [2] - The fund has generated an estimated floating profit of approximately 2.0936 million CNY today [2] Fund Performance - The Ping An CSI Medical Innovation ETF (516820) was established on June 9, 2021, with a current size of 1.532 billion CNY. Year-to-date returns are 16.05%, ranking 3225 out of 4216 in its category, while the one-year return is 7.22%, ranking 3400 out of 3877 [2] - Since inception, the fund has experienced a loss of 61.1% [2] Fund Management - The fund is managed by Ong Xin and Bai Guiyao. Ong Xin has been in the position for 1 year and 320 days, with a total asset size of 3.68 billion CNY, achieving a best return of 53.13% and a worst return of -15.51% during his tenure [3] - Bai Guiyao has been managing the fund for 127 days, with a total asset size of 4.23 billion CNY, achieving a best return of 25.61% and a worst return of -0.69% during his tenure [3]

Group 1 - Core viewpoint: Huadong Medicine (000963.SZ) reported its Q3 2025 results, highlighting significant institutional ownership and changes in shareholding among various funds and investors [1][2][3] Group 2 - As of October 27, 2025, 32 institutional investors held a total of 1.205 billion shares of Huadong Medicine, representing 68.71% of its total share capital [1] - The top ten institutional investors collectively held 67.93% of the shares, with an increase of 0.71 percentage points compared to the previous quarter [1] - In the public fund sector, 10 funds increased their holdings, while 8 funds reduced their holdings, with a decrease of 0.50% in the latter category [2] - One social security fund, the National Social Security Fund 112 Portfolio, reported a slight decrease in holdings [2] - In the insurance sector, one insurance company increased its holdings by 0.3%, while one new insurance investor was disclosed [3] - Foreign investment saw an increase from one foreign fund, Hong Kong Central Clearing Limited, with a rise of 0.69% in holdings [3]